These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38788030)

  • 1. Correlation between relative dose intensity of adjuvant S-1 chemotherapy and psoas muscle mass volume and survival after resection of pancreatic ductal adenocarcinoma: A retrospective study.
    Sakamoto T; Kishino M; Murakami Y; Miyatani K; Hanaki T; Shishido Y; Kihara K; Matsunaga T; Yamamoto M; Tokuyasu N; Fujiwara Y
    Medicine (Baltimore); 2024 May; 103(21):e38292. PubMed ID: 38788030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma.
    Li B; Shen S; You S; Zhang G; Gao S; Shi X; Wang H; Yin X; Xu X; Guo S; Jin G
    BMC Cancer; 2021 May; 21(1):612. PubMed ID: 34034684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the significance of adjuvant chemotherapy in patients with stage ⅠA pancreatic ductal adenocarcinoma.
    Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Matsunaga Y; Shiihara M; Yamamoto M
    Pancreatology; 2021 Apr; 21(3):581-588. PubMed ID: 33579600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Impact of Relative Dose Intensity of Adjuvant Chemotherapy With S-1 on Pancreatic Ductal Adenocarcinoma.
    Matsushima H; Adachi T; Hidaka M; Yamashita M; Hamada T; Fukui S; Tanaka T; Imamura H; Yoshino K; Kugiyama T; Kitasato A; Hara T; Soyama A; Kobayashi K; Sumida Y; Kuroki T; Eguchi S
    Anticancer Res; 2022 Jun; 42(6):3133-3141. PubMed ID: 35641261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors influencing relative dose intensity.
    Yabusaki N; Fujii T; Yamada S; Murotani K; Sugimoto H; Kanda M; Nakayama G; Koike M; Fujiwara M; Kodera Y
    Medicine (Baltimore); 2016 Jul; 95(29):e4282. PubMed ID: 27442667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
    Oba A; Ban D; Kirimura S; Akahoshi K; Mitsunori Y; Matsumura S; Ochiai T; Kudo A; Tanaka S; Minoru T
    J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):480-8. PubMed ID: 27247050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late start and insufficient S-1 dose in adjuvant chemotherapy can lead to poor prognosis in stage II/III gastric cancer.
    Miyatani K; Saito H; Shimizu S; Kono Y; Murakami Y; Shishido Y; Matsunaga T; Fukumoto Y; Fujiwara Y
    Int J Clin Oncol; 2019 Oct; 24(10):1190-1196. PubMed ID: 31104175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-tumour evaluation with MRI and radiomics features to predict the efficacy of S-1 for adjuvant chemotherapy in postoperative pancreatic cancer patients: a pilot study.
    Liang L; Ding Y; Yu Y; Liu K; Rao S; Ge Y; Zeng M
    BMC Med Imaging; 2021 Apr; 21(1):75. PubMed ID: 33902469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S-1 vs. gemcitabine as an adjuvant therapy after surgical resection for ductal adenocarcinoma of the pancreas.
    Okabayashi T; Shima Y; Iwata J; Morita S; Sumiyoshi T; Kozuki A; Tokumaru T; Iiyama T; Kosaki T; Kobayashi M; Hanazaki K
    World J Surg; 2014 Nov; 38(11):2986-93. PubMed ID: 25104544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas.
    Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Ohge H; Sueda T
    J Gastrointest Surg; 2009 Jan; 13(1):85-92. PubMed ID: 18704593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphatic invasion is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with gemcitabine or S-1.
    Aoyama T; Murakawa M; Katayama Y; Shiozawa M; Ueno M; Morimoto M; Yoshikawa T; Rino Y; Masuda M; Morinaga S
    Hepatogastroenterology; 2015; 62(138):472-7. PubMed ID: 25916085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Significance of Neoadjuvant Chemotherapy With Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma.
    Suzuki T; Mori S; Shimizu T; Tago K; Harada N; Park KH; Sakuraoka Y; Shiraki T; Iso Y; Aoki T; Kubota K
    In Vivo; 2019; 33(6):2027-2035. PubMed ID: 31662534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
    Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
    Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Body weight loss after surgery affects the continuity of adjuvant chemotherapy for pancreatic cancer.
    Morita Y; Sakaguchi T; Kitajima R; Furuhashi S; Kiuchi R; Takeda M; Hiraide T; Shibasaki Y; Kikuchi H; Konno H; Takeuchi H
    BMC Cancer; 2019 May; 19(1):416. PubMed ID: 31046709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
    Uesaka K; Boku N; Fukutomi A; Okamura Y; Konishi M; Matsumoto I; Kaneoka Y; Shimizu Y; Nakamori S; Sakamoto H; Morinaga S; Kainuma O; Imai K; Sata N; Hishinuma S; Ojima H; Yamaguchi R; Hirano S; Sudo T; Ohashi Y;
    Lancet; 2016 Jul; 388(10041):248-57. PubMed ID: 27265347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The high stromal SPARC expression is independently associated with poor survival of patients with resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine in combination with S-1 or adjuvant gemcitabine alone.
    Shintakuya R; Kondo N; Murakami Y; Uemura K; Nakagawa N; Okano K; Takahashi S; Sueda T
    Pancreatology; 2018 Mar; 18(2):191-197. PubMed ID: 29295776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Society based on real-world data.
    Tomimaru Y; Eguchi H; Inoue Y; Nagakawa Y; Ohba A; Takami H; Unno M; Yamamoto T; Kawakatsu S; Hayashi T; Higuchi R; Kitagawa H; Hattori S; Fujii T; Hirooka Y; Igarashi H; Kitano M; Kuroki T; Masamune A; Shimizu Y; Tani M; Tanno S; Tsuji Y; Yamaue H; Satoi S; Takeyama Y;
    Cancer; 2023 Mar; 129(5):728-739. PubMed ID: 36504020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic significance of combined geriatric nutritional risk index and psoas muscle volume in older patients with pancreatic cancer.
    Sakamoto T; Yagyu T; Uchinaka E; Miyatani K; Hanaki T; Kihara K; Matsunaga T; Yamamoto M; Tokuyasu N; Honjo S; Fujiwara Y
    BMC Cancer; 2021 Mar; 21(1):342. PubMed ID: 33789590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal adenocarcinoma.
    Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):109-120. PubMed ID: 33825991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma.
    Shinkawa H; Uenishi T; Takemura S; Sakata C; Urata Y; Nozawa A; Hamano G; Kinoshita M; Kubo S
    Hepatogastroenterology; 2015; 62(137):169-74. PubMed ID: 25911890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.